Login to Your Account

Pharma: Other News To Note

Monday, June 25, 2012
• Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA issued a complete response letter for the firm's supplemental new drug application for Xarelto (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription